APOE Christchurch variant blocks tau and alpha-synuclein build-up in mice

A rare variant of the APOE gene, known as the Christchurch mutation, stopped two disease-associated proteins from accumulating in the brains of mice. Researchers at Oregon Health & Science University (OHSU) report in Cell Reports that the variant blocked both tau and alpha-synuclein, the latter being a hallmark of Parkinson's disease and Lewy body dementia. The finding is preclinical, but it extends the possible reach of APOE-based gene therapy beyond Alzheimer's disease.

From Alzheimer's to Parkinson's

The Christchurch variant was first identified in New Zealand. It drew wider attention in 2019, when a woman from Colombia who carried it was reported to have delayed dementia symptoms despite a genetic profile that would normally lead to Alzheimer's disease. Work in animal models has since indicated that the variant limits aggregation of tau, a protein central to Alzheimer's pathology.

The OHSU team, whose senior author is Vivek Unni, associate professor of neurology in the OHSU School of Medicine, set out to test whether the effect reaches further. According to the university, this is the first study to connect the Christchurch variant with Parkinson's-related pathology.

What the experiments showed

The researchers used mouse models bred to be prone to accumulating alpha-synuclein and tau in the brain. They then introduced the Christchurch mutation into the mouse APOE gene and compared the outcomes. The paper, led by first author Carlos M. Soto-Faguás, is titled "Mouse APOE Christchurch protects against Aβ-induced tau and α-synuclein aggregation".

In every case described, mice carrying the variant did not accumulate tau or alpha-synuclein, even though they were predisposed to do so. The results therefore support the idea that the variant protects against the protein build-up thought to drive both Alzheimer's and Parkinson's disease, and not only against tau pathology.

Comparison with APOE-2

Gene therapies are already being developed around APOE-2, a more common APOE version that also appears to protect against Alzheimer's disease. Unni suggested that the Christchurch variant may offer stronger protection, saying it "acts like a super-APOE-2" in the mouse model used. That comparison applies only to this experimental system and has not been established in people.

Why it matters and what comes next

The work suggests that APOE biology may influence several protein-aggregation disorders through a shared mechanism, an idea that could interest researchers who normally study Alzheimer's and Parkinson's disease separately. It also gives gene therapy developers a second possible disease target for a variant that is already of interest.

Several caveats apply. The data come from genetically engineered mice, which model only parts of human disease. The study does not show that the variant prevents symptoms of Parkinson's disease or Lewy body dementia in people, nor that a therapy could deliver the same effect in an adult brain. The source article does not describe how the variant exerts its protective effect.

Unni's laboratory plans to extend its preclinical research, with the longer-term aim of building a case for industry investment in human trials of APOE Christchurch gene therapy. He estimated that testing the idea would take several years.

Source: Christchurch mutation points to potential gene therapy avenue for Parkinson's (Medical Xpress, 12 November 2026).

Image: AI-generated illustration.